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Abstract: Clinical trials are one of the key study designs in the evolving field of comparative
effectiveness research. Evaluating the effectiveness of interventions in real-world settings is complex and demands a rethinking of the traditional clinical trial approach as well as transformation
of the clinical trial landscape. Novel strategies and refinement of existing approaches have been
proposed to generate evidence that can guide health care stakeholders in their decision process.
The purpose of this review is to discuss clinical trial design approaches in the era of comparative effectiveness research. We will focus on aspects relevant to the type of clinical trial, study
population and recruitment, randomization process, outcome measures, and data collection.
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Comparative effectiveness research (CER) aims to provide health care stakeholders,
including patients, clinicians, and policymakers, with evidence necessary to make
informed health care decisions.1 One important aspect of CER is the generation of
evidence that is applicable to a broad patient population and reflects real-world circumstances, allowing efficient translation and implementation of findings into patient care.
Clinical trials are one of the key study designs in CER and can be utilized to evaluate
the effectiveness of a broad spectrum of health care interventions such as treatments,
behavioral interventions, clinical evaluation strategies, health care delivery methods,
and policy interventions.2 However, conducting a clinical trial in a real-world setting
is complex and demands a shift in the traditional clinical trial paradigm.3
The investment of over $1 billion in CER through the American Recovery and
Reinvestment Act of 2009 has resulted in a growing demand and interest in CER
in the research community in the USA. Funding agencies including the Agency for
Healthcare Research and Quality and the Patient-Centered Outcomes Research Institute
have issued proposal requests to develop CER infrastructure and conduct CER studies
including pragmatic clinical trials.4 The governmental commitment and investment in
CER provides the research community with exciting opportunities to address important
CER questions. However, many health researchers and decision makers may not yet
be familiar with clinical trial design features and concepts in the rapidly evolving CER
field. The purpose of this review is to provide a broad overview of clinical trial design
concepts in the context of CER and to discuss some aspects relevant to the design
and interpretation of clinical trials. Within the scope of this review, we will focus on
the definition of trial type, study population and recruitment, randomization process,
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o utcomes measures, and data collection. We will discuss
some methodological points to consider when designing a
clinical trial, acknowledging that we are unable to cover every
aspect that has been proposed in this evolving field.

Type of trial
Effectiveness or pragmatic trials have been proposed as
one key trial design in CER to generate evidence that can
be efficiently translated into patient care. An effectiveness
or pragmatic trial seeks to answer the question whether
an intervention works under usual conditions. An efficacy
or explanatory trial is designed to evaluate whether an
intervention works under ideal circumstances.5,6 These
distinctions also have implications for the design and
interpretation of the trial. A pragmatic/effectiveness trial is
designed to determine the effectiveness of an intervention
in a real-world setting and will include a broad spectrum of
patients. The trial will be embedded in routine care or reflect
real-world circumstances of patient care. The intervention
will be compared with an alternative intervention or usual
care. The trial design will allow a certain degree of flexibility in administering the intervention and in following up
patients without compromising the internal validity of the
trial. In contrast, to determine the efficacy of an intervention,
an efficacy/explanatory trial will enroll a selective patient
population, likely to be highly responsive to the intervention.
The intervention will be compared with placebo or a well controlled alternative intervention. The trial will be performed
in a tightly controlled study setting with little flexibility and
patients will be closely monitored and followed.6
Both efficacy and effectiveness trials add valuable
findings to the whole body of evidence and the choice of
trial should be guided by the underlying research question.
Understanding the purpose and design features of the trial are
important for the interpretation of the trial and the generalizability of trial results. Results of an efficacy trial indicating a
beneficial effect do not allow the conclusion that the intervention will always work in usual practice, whereas a “negative”
efficacy trial strongly suggests that the intervention would
not work under usual conditions. An intervention that has
been demonstrated to be effective under usual conditions
will probably show similar results under ideal circumstances,
whereas a “negative” effectiveness trial does not prove that
its intervention cannot work under other circumstances.
However, labels such as pragmatic or explanatory are an
oversimplification and imply a dichotomy. In reality, a trial is
rarely completely pragmatic or explanatory and will be on a
continuum between these two extremes. To provide guidance for
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trial design and to support trialists in the evaluation of the degree
of pragmatism, a pragmatic-explanatory continuum indicator
summary (PRECIS) tool has been developed by an international group of trialists.6 The PRECIS instrument describes ten
domains that affect the degree to which a trial is pragmatic or
explanatory (Table 1). The graphical representation of the ten
domains is a useful instrument to identify those domains that
are not as pragmatic or explanatory as the trial designer desires
(Figure 1). The PRECIS instrument has been primarily developed to guide the trial design at the planning stage but may also
have an application in peer reviews from study reports.
In a recently published study, the PRECIS criteria were
applied to the POWER (Practice-Based Opportunities for Weight
Reduction) trials.7 The POWER trials were three individual
studies designed to test the effectiveness of interventions for
obesity treatment in primary care settings. As part of a common National Institutes of Health funding mechanism, all
trials shared certain design features. Trial-specific elements
included different types of interventions and secondary outcome
measures. Two raters from each trial and three independent
raters were asked to rate the three studies on the ten PRECIS
domains, using a 0–4 point scale (0, completely explanatory;
4, completely pragmatic). In Figure 1, the PRECIS diagram of
the “POWER Hopkins” study7 is presented. Overall, all trials
were rated in a moderate range on the PRECIS scale, with mean
scores ranging from 1.82 to 2.36. The inter-rater reliability on
the composite PRECIS score was high (r=0.88) and there was
moderate agreement on the individual level. Despite the small
sample size, the study is an important first step to evaluate
the applicability of the PRECIS criteria in post hoc reviews.
Table 1 Ten domains of the PRECIS model
Participants
Participant eligibility criteria
Interventions and expertise
Experimental intervention – flexibility
 Experimental intervention – practitioner expertise
Comparison intervention – flexibility
Comparison intervention – practitioner expertise
Follow-up and outcomes
Follow-up intensity
Primary trial outcome
Compliance/adherence
Participant compliance with “prescribed” intervention
Practitioner adherence to study protocol
Analysis
Analysis of primary outcome
Note: Reprinted from the Journal of Clinical Epidemiololgy, 62(5), Thorpe KE,
Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator
summary (PRECIS): a tool to help trial designers, 464–475, Copyright 2009, with
permission from Elsevier.6
Abbreviation: PRECIS, pragmatic-explanatory continuum indicator summary.
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Figure 1 Pragmatic-explanatory continuum indicator summary (PRECIS) tool examples.
Notes: (A) To create a wheel graph, mark each spoke to represent the location on the explanatory (hub) to pragmatic (“rim”) continuum for each domain and connect
the dots. Reprinted from the Journal of Clinical Epidemiololgy, 62(5), Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum indicator summary
(PRECIS): a tool to help trial designers, 464–475, Copyright 2009, with permission from Elsevier.6 (B) Example of a PRECIS tool that indicates a highly pragmatic trial.
(C) Example of a PRECIS tool that indicates a highly explanatory design. (D) The study was rated by nine raters on a scale from 0 to 4. The mean value for each criterion
was graphed. Copyright ©. Adapted from Health Research and Educational Trust. Glasgow RE, Gaglio B, Bennett G, et al. Applying the PRECIS criteria to describe three
effectiveness trials of weight loss in obese patients with comorbid conditions. Health Serv Res. 2012;47(3 Pt 1):1051–1067, with permission from John Wiley & Sons, Ltd.7
Abbreviations: E, explanatory; POWER, Practice-Based Opportunities for Weight Reduction.

In addition, the authors introduced a scoring system to more
objectively quantify the degree of pragmatism. It is unclear to
date how the degree of pragmatism of a trial will impact the
adoption and implementation of findings in patient care. Hopefully, future studies in the field will help to define how the choices
made at the design stage can affect the translation into care.
Another important concept to further define and to classify clinical trials is according to the underlying research
hypothesis.
In the context of CER, noninferiority trials are important since they can be used to guide the decision process
between two interventions that have similar therapeutic
effects but differ in terms of other aspects relevant to stakeholders, such as costs, adverse event profile, and/or route of
administration.8 The noninferiority trial aims to show that the
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difference between the treatment of interest and the reference treatment (active control) is less than the prespecified
noninferiority margin.9 Figure 2 displays a schematic presentation of the possible scenarios of observed treatment
differences in noninferiority trials.
The design and quality of a noninferiority trial depends on
the proper choice of the noninferiority margin. Defining the
noninferiority margin can be complex and quiet challenging.
Factors that can provide guidance in the development of noninferiority are evidence from previous studies, preliminary
data, and/or clinical judgment. Sufficient evidence from
previous efficacy studies or preliminary data is very helpful
in allowing the trialists to make reasonable assumptions about
an anticipated effect of the reference treatment. However,
some points should be considered when utilizing previous
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Figure 2 Possible scenarios of observed treatment differences in non-inferiority trials.
Notes: Error Bars indicate 2-sided 95% confidence intervals (CIs). Δ indicates the non-inferiority margin. (A), if the CI lies wholly left of zero, the new treatment is superior.
(B and C), if the CI lies to the left of Δ and includes zero, the new treatment is noninferior but not shown to be superior. (D and E), if the CI includes Δ and zero, the
difference is nonsignificant but the result regarding noninferiority is inconclusive. (F), if the CI is wholly above Δ, the new treatment is inferior. Copyright © (2006) American
Medical Association. All rights reserved. Adapted from Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and
equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006;295(10):1152–1160.8

evidence for the definition of the noninferiority margin. First,
patient populations enrolled in previous efficacy trials may be
highly selective and not representative of the targeted population in the noninferiority trial. Second, trials demonstrating
a beneficial effect of the reference treatment must have been
conducted recently enough to ensure that no substantial
changes in medical practice and important medical advances
occurred. Third, the chosen endpoint in the planned trial must
be sensitive to the proposed effect in both the intervention and
reference group to demonstrate a true difference.10
Many trials have to enroll a chronic disease population in
order to address important CER hypotheses that are pertinent
to real-world patient care. Designing a noninferiority trial
in a patient population with chronic disease is particularly
challenging as previous evidence about possible anticipated
effect sizes may be lacking for this specific patient population, cointerventions may occur, and patients may change
their treatment regime throughout the trial. In addition,
efficacy studies can fail to distinguish between treatment and
placebo effect, or the effect can vary according to the type
of placebo used in some chronic conditions. This makes a
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noninferiority trial difficult to design.11 Some strategies, such
as stratification, are available at the design stage to control for
anticipated or known cointerventions. However, stratification
of multiple factors complicates the trial design and it may be
impossible to anticipate any possible cointervention upfront.
Although the randomization process ideally balances the
possible cointerventions between the groups, the possibility that the effect will be diluted and results will be biased
toward the null cannot be ruled out. In the context of a noninferiority trial, a bias toward the null has special implications
as it can lead to the false conclusion of noninferiority.

Study population and recruitment
Recruitment of a large representative study population
in a timely and cost-efficient manner is one of the major
challenges in the CER field. To assure generalizability of
results, an effectiveness trial aims to include a broad and
representative study population. In particular, the inclusion
of populations that have been traditionally underrepresented in clinical trials such as the elderly, minorities, and
underserved populations is an important aspect of CER. Some
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comparative effectiveness trials addressing important gaps
in the field require a large sample size to demonstrate effectiveness of interventions and may therefore not be feasible to
conduct. A long recruitment process is not desirable because
it increases costs and unnecessarily delays the translation
of evidence into patient care. Utilization of existing health
care infrastructures, such as registries, health insurances, and
primary care networks, for trial recruitment is a promising
approach to overcome some of these challenges.
TASTE (Thrombus Aspiration in ST-Elevation Myocardial
Infarction in Scandinavia) is an example of a recently
published clinical trial that utilized the infrastructure of a
population-based national registry, SCAAR (the Swedish
Coronary Angiography and Angioplasty Registry), to establish
feasibility and to facilitate patient enrollment and data collection.12 This government-funded registry included data from all
29 Swedish and one Icelandic coronary intervention centers.
The patients were randomized using an online randomization
tool within the SCAAR database and the intervention was
embedded in routine care. Using the existing registry infrastructure, the investigators were able to recruit and randomize
over 6,000 patients between June 2000 and September 2012
at an incremental cost of $50 per patient.13
MI FREE (Post-Myocardial Infarction Free Rx Event
and Economic Evaluation Trial) is an example of a cluster
randomized trial that was conducted within a large insurance system (Aetna) in the USA. The aim of the trial was to
compare the effectiveness of full prescription drug coverage
for statins, beta-blockers, angiotensin-converting enzyme
inhibitors, and angiotensin II receptor blockers versus usual
prescription coverage in the secondary prevention of myocardial infarction. Hospital discharge claims were evaluated
by the insurance provider to identify eligible patients with
a discharge diagnosis of new acute myocardial infarction.
Randomized assignments to the two insurance benefits
groups occurred at the level of the plan sponsor. During the
total study period of 34 months, 5,855 patients were included
in the trial and followed for a minimum of 1 year. Outcome
information has been ascertained through Aetna’s health care
utilization databases.14
Although both the registry-based and insurance-based
designs are promising and novel concepts of efficient
and cost-effective recruitment of a large number of trial
participants, there are some limitations to these designs
worth considering. Despite the broad inclusion criteria of
the TASTE trial, approximately 40% of registry patients
did not enter the trial, mainly because they were unable
to provide informed consent. These patients had a higher
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30-day mortality rate when compared with the enrolled
patient population, which limits the generalizability of the
study results.12 Choudry and Shrank shared their experience
with designing the MI FREE trial in an insurance setting and
discussed several challenges.15 Noteworthy in the context
of patient recruitment and study population characteristics,
the potential inaccuracy of claims-based identification
methods, the impact of claims lag on the timely enrollment
of subjects, and the reluctance of patients to participate in
insurance-based interventions were described as challenges
the trialists faced throughout the trial. In addition, the trial
included neither patients over 65 years old as they receive
health benefits through Medicare nor those patients who
received health benefits through other mechanisms.
Recruitment of patients through primary care practices and
community-based health care providers is another important
strategy for assembling a study population that reflects realworld patient care. In particular, primary care practices may
give access to multimorbid and elderly patients, a population
typically underrepresented in clinical trials.16 Practice-based
research networks have been developed and initiated worldwide, and provide an infrastructure for conducting research in
primary care settings.17 Recruitment of participants in primary
care settings may be associated with some unique challenges.
When clinicians and/or practice staff are involved in the
screening and enrolling process, barriers such as lack of time
and resources, concerns with the study protocol, and the possible negative impact on the patient-clinician relationship can
affect the success of recruitment. In addition, some primary
care practices lack the infrastructure necessary to recruit and
conduct research.18 Proposed strategies to overcome some of
these recruitment difficulties in primary care include identification of eligible patients through electronic health records and
minimizing the impact on general practice operations, but it is
unclear to date whether these strategies can be applied to and
adopted by the majority of primary care settings or whether
individually tailored strategies are necessary.19–21
Utilization of existing health care infrastructures for
patient recruitment may not assure the participation of ethnic
minorities and other underrepresented populations in clinical
trials. Factors impacting minority clinical trial enrollment
range from individual to policy level factors, so strategies to
enhance minority recruitment possibly require interventions
at multiple levels. A framework to develop and implement
an institutional strategy to increase minority recruitment in
therapeutic cancer trials at a US academic institution has been
published recently.22 Within 5 years after implementation of
structural changes on four different levels, minority accrual
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to therapeutic trials increased from 12% to 14%. Another
strategy that has been proposed to enhance minority participation in clinical research is engagement of community
members in research activities through community-based
participatory research.23 Both implementing changes at
the institutional level and community-based participatory
research are promising approaches to address the underrepresentation of minority groups in clinical trials. However, these
approaches require long-term commitment and support from
institutions and researchers to implement structural changes
at the institutional level as well as to build and sustain community partnerships.

Randomization process
Many research questions in the CER field do not allow
randomization at the individual level. They may require a
cluster randomized trial design because interventions are
delivered at the system level or because individual allocation
of the intervention creates the possibility of contamination
between those who receive the intervention and those who do
not, either through the patients or the provider who delivers
the intervention. In a cluster randomized trial, the intervention
is randomly assigned to a group (ie, cluster) of patients and
each patient within a cluster receives the same intervention.
James et al provide an example of a cluster randomized trial
designed to test system interventions to promote colon cancer
screening among underinsured and uninsured patients.24 In
this pragmatic clinical trial, community health centers will
be randomly assigned to evidence-based implementation
strategies for increasing colorectal cancer screening. The primary outcome, colon cancer screening rates, will be assessed
at the patient level. Implementation outcomes, defined
according to the RE-AIM (Reach, Efficacy/Effectiveness,
Adoption, Implementation, and Maintenance) conceptual
framework,25 will be collected at the patient, provider, and
practice levels.
Compared with an individual randomized trial, the cluster
trial is more complex to design and execute, and poses some
methodological challenges.26,27 Allocating interventions to
a cluster of patients has important implications for both the
sample size calculations and the analyses approach. Patients
within a cluster may share certain similarities and cannot be
considered as independent observations. Independence is
one important assumption of standard statistical tests used
for sample size calculations, and the trial designer needs to
account for possible correlations of patient characteristics
including the outcome of interest within a cluster. The
intraclass correlation coefficient, defined as the ratio of the
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variance between clusters divided by the sum of the variance
between clusters plus the variance among patients within a
cluster, quantifies the amount of agreement in a characteristic
(ie, the primary endpoint of a study) between individuals of
the same cluster.26 Estimation of the intraclass correlation
coefficient is one key component of the trial design as it
informs the calculation of the design effect, an inflation factor
used to adjust standard sample size calculations. The sample
size for a cluster randomized trial is commonly estimated
by calculating the number of participants for an individual
randomized trial with the same effect size, significance level,
and power, and then multiplying the sample size by the design
effect.28 Failure to incorporate the design effect into the
sample size calculations results in a possible underestimation
of the sample size necessary to detect the anticipated outcome
difference between the intervention groups. Estimation of a
design effect in the planning stages of a cluster randomized
trial is challenging, particularly when preliminary data are
not available to make reasonable assumptions.
Although accounting for correlations in sample size
calculations and in the analyses approach is an important
aspect in the design of cluster randomized trials, many cluster
randomized trials still use inappropriate statistical methods
or fail to report important methodological aspects. In a
systematic review of 73 cluster randomized trials in residential facilities, only 27% reported accounting for clustering in
sample size calculations and 74% in the analyses approach.29
There is some evidence that the quality of reporting cluster randomized trials has improved in a few aspects since
the introduction of the extended Consolidated Standards
of Reporting Trials (CONSORT) statement. However, no
improvements were observed in reporting essential methodological features.28,30 In a recently published systematic
review, journal endorsement of the CONSORT statement
was not associated with trial quality, but trials with support
from statisticians and/or epidemiologists were more likely
to account for clustering in sample size calculations and
analyses.29
One unique challenge of cluster randomized trials is that
successful randomization at the system level, resulting in
balanced characteristics between clusters, does not guarantee that characteristics are balanced at the individual level.
Imbalance on the individual level is a threat to the internal
validity of study results, and strategies to address possible
imbalances should be considered at the design stage of the
trial. Simple randomization techniques may pose a higher
risk for covariate imbalance in cluster randomized trials,
and more complex allocation techniques such as restricted
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randomization including matching, stratification, and minimization, as well as covariate-constrained randomization
techniques, have been proposed to minimize the risk of
imbalances.31

Outcome measures
Traditionally, primary and secondary endpoints in clinical
trials have been chosen to be well defined clinically relevant
outcome measures, such as mortality and disease-free survival, and measures indicating physiological and disease
status changes. Although outcomes such as mortality and
disease-free survival are certainly important to multiple
stakeholders and should be part of the decision process,
these endpoints do not reflect the patient’s experience and
perspectives about the benefits and harms of an intervention.
The value of incorporating patient-reported outcomes that
allow conclusions about the effect of an intervention on
patient’s symptoms, functional status, and quality of life has
been extensively discussed and broadly accepted by the CER
community as an important strategy to generate evidence
that matters to patients and helps engage them in the clinical
decision process.
Given the variety of instruments available to assess
patient-reported outcomes, one of the challenges at the trial
planning stage is to choose the appropriate outcome measure.
A patient-reported outcome can be defined as a self-reported
measure of patient health status, such as health-related quality of life, functional status, and patient satisfaction. Several
patient-reported outcome measures including health-related
quality of life have their roots in the social sciences using
different conceptual frameworks as a basis for the instrument
development.32 Instrument development is a complex process
that involves patient input in qualitative assessments of the
instrument, validation of the scoring system, and possibly
different translations, and quantitative assessment of how to
interpret score differences and establishment of meaningful
thresholds.33,34 Clinical researchers may not yet be familiar
with a meaningful interpretation of the mostly multidimensional instruments, and it can be challenging to choose an
instrument that best suits the specific objectives of the trial.
Criteria to evaluate the appropriateness of an instrument
include evidence for its reliability and validity in relation
to the study population of the trial and its responsiveness to
change.35 Patient-reported outcomes are often derived from
multi-item instruments and summarized in scores, and may
be less intuitive to interpret compared with outcomes such
as mortality and disease-free survival. Some patient-reported
outcome instruments allow derivation and definition of
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multiple endpoints (ie, overall score at the end of the study,
mean change of score during follow-up, percent change of
baseline score) and a careful decision about the endpoint
definition and anticipated magnitude of the effect size should
be taken at the designing stage to avoid selective reporting
of results and to assure appropriate power and sample size
estimates.36–38
Several initiatives have been established to develop and
standardize patient-reported outcome measures. The Patient
Reported Outcomes Measurement Information System
(PROMIS) is a US National Institutes of Health-funded
network of outcomes researchers with the overarching goal
of developing a framework for patient-reported outcomes.39
Following the World Health Organization definition of
health, PROMIS distinguishes between three areas of health
(physical, mental, and social) and further defines subdomains,
including physical function, fatigue, pain, emotional distress,
social function, and global health. PROMIS measures were
developed using data from general population samples
across multiple chronic conditions. One advantage is that
these universally relevant measures with a common metric
can be compared across diseases and conditions. However,
universally relevant measures may not be as sensitive as
disease-specific instruments to assess the health status and
to detect changes over time in certain disease populations.
C ontroversy currently exists about the utilization of
universally relevant measures versus disease-specific measures, and future studies are warranted to better understand
the relationship between these two types of measures and
their application in different disease populations.40,41
Heterogeneity of outcomes measures makes it challenging
to synthesize existing evidence through meta-analyses and
systematic reviews. Achieving consensus about endpoints
including patient-reported outcomes in clinical trials is
crucial. Working groups worldwide have been launched to
define and standardize disease-specific core outcome sets
that are comparable across trials.42,43

Data collection and follow-up
Integration of electronic medical record information into
clinical trials through automated processes is an emerging
concept in the clinical trial enterprise.44,45 Effectiveness trials
embedded in primary care and clinical settings can utilize
patient data that have been routinely collected in clinical
care through electronic medical records. This approach has
advantages, as it allows collection of baseline and longterm follow-up data for large and highly representable trial
populations in a timely and cost-effective manner. Patients
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eligible for the trial can be identified automatically and
utilization of electronic record information allows comparisons of enrolled trial patients with those not enrolled
to monitor the representativeness of the trial population.
Linkages to other data sources, including national death
registers, hospital records, and registries, allow capture of
important outcome information and reduce the amount of
loss to follow-up. Self-reported patient information collected
through electronic devices can be linked to the trial database,
enriching the trial data and allowing incorporation of patientreported outcomes.46
Data collection and patient follow-up through utilization
and linkage of electronic health records provides the
CER enterprise with exciting opportunities. However, the
electronic health record has not been primarily designed
for research purposes, which poses some major challenges.
The data captured in an electronic health record may
reflect the interactions of the patient with the health care
system rather than a well defined disease status. Strategies
to accurately “phenotype” patients according to the available electronic health record information have been developed, and efforts are underway to standardize and validate
procedures across electronic medical record systems and
institutions.47 Data quality is another issue that has been
broadly discussed in the context of use of electronic medical
records for research purposes, including data completeness
and accuracy. Missing data, erroneous data, inconsistencies
among providers, across institutions, and over time, as well
as data stored in noncoded text notes, are some of the data
challenges identified.48
Complete, valid, and reliable baseline, follow-up, and
endpoint data are crucial to assure high internal validity
of trial results. A recently published study from Scotland
compared cardiovascular endpoint detection through record
linkage of death and hospitalization records with events that
were reported through a standard clinical trial mechanism in
the West of Scotland Coronary Prevention study.49 The study
showed excellent matching between record linkage and endpoints assessed through standard trial mechanisms for unambiguous endpoints such as mortality, but complex diagnoses
such as transient ischemic attack/stroke and identification of
subsequent events was associated with imperfect matching
of events. Important to note, the study was conducted in
Scotland, a country with a unified health care system that
facilitates patient follow-up. In a more scattered health care
system with frequent insurance coverage transitions like the
USA, patient follow-up through electronic health record linkage may be limited and prone to missing information. Missing
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information can introduce bias and lead to false conclusions
of intervention effectiveness. Although there are analytical
strategies to handle missing information, the best approach
is to prevent occurrence of missing information.50 Further
studies will hopefully help to identify the best approach
for electronic medical records’ utilization in clinical trials
without compromising data quality and accuracy.

Conclusion
The evolving field of CER requires a shift in the traditional
clinical trial paradigm and will continue to challenge and
change the clinical trials’ landscape. Careful study design
and consistent use of terminology and standards in reporting of trial results will facilitate meaningful interpretation
and translation of findings. Incorporation of patient-reported
outcomes into clinical trials will provide stakeholders
with important information on patient’s experiences and
perspectives. Identification of gaps in the field will foster
development of novel methodological approaches. Key to
a successful transition of the clinical research enterprise is
investment in sustainable research infrastructures, further
development and refinement of methodological approaches,
and continuing training of the research community in relevant
CER methods.
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